VIRGINIA LOTTI¹, GAETANO DE SIENA², STEFANO BACCI^3,*

BIOCELL, Vol.48, No.12, pp. 1751-1759, 2024, DOI:10.32604/biocell.2024.057904 - 30 December 2024

Abstract Background: Impaired wound healing is one of the most well-known complications of type 2 diabetes mellitus. Experimental evidence suggested that treatment with Exendin-4, a glucagon-like peptide-1 agonist displaying a wide range of antidiabetic effects, can promote tissue regeneration. Objectives: Thus, this study aimed to examine the efficacy of topical treatment with Exendin-4 in accelerating wound healing in normoglycemic and hyperglycemic mice. Methods: For this purpose, two wounds inflicted on the back skin of 12 normo- and 12 hyperglycemic mice were injected intradermally with either saline solution or Exendin-4. Wounds were collected at the time of abrasion… More >

POOJA JAISWAL¹, VERSHA TRIPATHI¹, ANSHUL ASSAIYA², DHARMENDRA KASHYAP³, RAHUL DUBEY⁴, ANAMIKA SINGH⁴, JANESH KUMAR², HEM CHANDRA JHA³, RAJESH SHARMA⁵, AMIT KUMAR DIXIT⁶, HAMENDRA SINGH PARMAR^1,*

BIOCELL, Vol.46, No.12, pp. 2645-2657, 2022, DOI:10.32604/biocell.2022.021754 - 10 August 2022

Abstract Triple-negative breast cancer (TNBC) cell line MDA-MB-231 is known for Warburg metabolism and defects in mitochondria. On the other hand, dipeptidyl peptidase-IV (DPP-IV) inhibitors such as sitagliptin and vildagliptin and GLP-1 agonist exendin-4 are known to improve mitochondrial functions as well as biogenesis, but no study has evaluated the influence of these drugs on mitochondrial biogenesis on metastatic breast cancer cell line. We have recently reported anticancer effects of 5-aminoimidazole-4-carboxamide riboside on MDA-MB-231 cells via activation of AMP-dependent kinase (AMPK), which activates the downstream transcription factors PGC-1α, PGC-1β, or FOXO1 for mitochondrial biogenesis; above-mentioned incretin-based… More >

ATTALLA F. EL-KOTT^1,2,*, AYMAN E. EL-KENAWY³, EMAN R. ELBEALY⁴, ALI S. ALSHEHRI¹, HEBA S. KHALIFA², MASHAEL MOHAMMED BIN-MEFERIJ⁵, EHAB E. MASSOUD^6,7,8, AMIRA M. ALRAMLAWY⁹

BIOCELL, Vol.45, No.5, pp. 1337-1353, 2021, DOI:10.32604/biocell.2021.015464 - 12 July 2021

Abstract This study examined if the anti-tumorigenesis effect of Exendin-4 in HT29 and HCT116 colorectal cancer (CRC) involves modulation of SIRT1 and Akt/GSR3K/β-catenin/NF-κB axis. HT29 and HCT116 cells were treated either with increasing levels of Exendin-4 (0.0-200 µM) or with Exendin-4 (at its IC₅₀) in the presence or absence of EX-527 (10 µM/a selective SIRT1 inhibitor) or Exendin-4 (9-39) amide (E (9-39) A) (1 µM/an Exendin-4 antagonist). In a dose-dependent manner, Exendin-4 inhibited cell survival, but enhanced levels of lactate dehydrogenase (LDH) and single-stranded DNA (ssDNA) in both HT29 and HCT116. In both cell lines and at… More >